Evidence map›Paper›PMID 39222955›Full record

ArticleHuman vaccines & immunotherapeutics2024

Post-marketing safety study to evaluate pregnancy outcomes among recipients of hepatitis B vaccines.

Katia J Bruxvoort, Lina S Sy, Jeff Slezak, Bradley K Ackerson, Lei Qian, Sijia Qiu, Zendi Solano, Kristi Reynolds

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Katia J BruxvoortDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0001-8277-2431
Lina S SyDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Jeff SlezakDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Bradley K AckersonDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Lei QianDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Sijia QiuDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Zendi SolanoDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Kristi ReynoldsDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HepB-CpG is a licensed adjuvanted two-dose hepatitis B vaccine for adults, with limited data on exposure during pregnancy. We assessed the risk of pregnancy outcomes among individuals who received HepB-CpG or the 3-dose HepB-alum vaccine ≤28 d prior to conception or during pregnancy at Kaiser Permanente Southern California (KPSC). The pregnancy cohort included KPSC members aged ≥18 y who received ≥1 dose of hepatitis B vaccine (HepB-CpG or HepB-alum) at KPSC outpatient family or internal medicine departments from August 2018 to November 2020. We followed these individuals through electronic health records from the vaccination date until the end of pregnancy, KPSC health plan disenrollment, or death, whichever came first. Among 81 and 125 eligible individuals who received HepB-CpG and HepB-alum, respectively, live births occurred in 84% and 74%, spontaneous abortion occurred in 7% and 17% (adjusted relative risk [aRR] 0.40, 95% CI: 0.16-1.00), and preterm birth occurred in 15% and 14% of liveborn infants (aRR 0.97, 95% CI 0.47-1.99). No major birth defects were identified through 6 months of age. The study found no evidence of adverse pregnancy outcomes for recipients of HepB-CpG in comparison to HepB-alum.

Indexed as

Hepatitis BHepatitis B VaccinesPregnancy OutcomeProduct Surveillance, PostmarketingAbortion, SpontaneousAdjuvants, ImmunologicAdolescentAdultCaliforniaFemaleHumansInfant, NewbornLive BirthPregnancyPremature BirthVaccinationAdjuvants, ImmunologicHepatitis B Vaccinesbirth defectsHepatitis B vaccineHepB-CpGpregnancysafety

Identifiers

PMID39222955
PMCPMC11370903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.